^
Association details:
| Biomarker: | MSI-H/dMMR + POLE mutation |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | Jemperli (dostarlimab-gxly) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors
Published date:
11/01/2023
Excerpt:
Patients received 500 mg of dostarlimab intravenously every 3 weeks for 4 doses, then 1000 mg every 6 weeks until disease progression, discontinuation, or withdrawal...Three of 6 patients with MMRp/POLE-altered tumors achieved a response (including 1 patient with CRC who achieved a CR)...
DOI:
10.1001/jamanetworkopen.2023.41165
Trial ID:
